Rapport Therapeutics Commences Separate Underwritten Public Offerings Of $200M Of Shares And $150M Aggregate Principal Amount Of Convertible Senior Notes Due 2032
Rapport Therapeutics, Inc. (NASDAQ:RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients
Rapport Therapeutics is raising $350 million total through two offerings: stock and debt. When a company raises money like this, watch whether they use it wisely on their medicines.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.